Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Concord Biotech Ltd
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 241 | 273 | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 |
| Expenses + | 129 | 144 | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 |
| Operating Profit | 112 | 129 | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 |
| OPM % | 46% | 47% | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% |
| Other Income + | 9 | 12 | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 |
| Profit before tax | 106 | 126 | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 |
| Tax % | 26% | 26% | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% |
| Net Profit + | 79 | 94 | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 |
| EPS in Rs | 7.56 | 8.94 | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 |
Financials of Concord Biotech Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 239 | 276 | 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,159 |
| Expenses + | 133 | 145 | 212 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 714 |
| Operating Profit | 105 | 131 | 127 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 445 |
| OPM % | 44% | 48% | 37% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 38% |
| Other Income + | 11 | 8 | 36 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 43 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation | 10 | 10 | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 69 |
| Profit before tax | 106 | 129 | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 418 |
| Tax % | 34% | 33% | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | |
| Net Profit + | 70 | 87 | 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 315 |
| EPS in Rs | 76.32 | 94.78 | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 35.65 | 30.13 |
| Dividend Payout % | 22% | 25% | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% |
Financials of Concord Biotech Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 268 | 329 | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 | 1,802 | 1,815 |
| Borrowings + | 35 | 36 | 22 | 9 | 52 | 89 | 62 | 32 | 10 | 3 | 2 |
| Other Liabilities + | 55 | 74 | 69 | 71 | 118 | 94 | 144 | 191 | 164 | 219 | 194 |
| Total Liabilities | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,021 |
| Fixed Assets + | 104 | 110 | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | 790 |
| CWIP | 19 | 70 | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 | 74 |
| Investments | 42 | 43 | 151 | 229 | 199 | 142 | 74 | 138 | 244 | 335 | 354 |
| Other Assets + | 202 | 225 | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | 804 |
| Total Assets | 367 | 448 | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,021 |
Financials of Concord Biotech Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 79 | 155 | 167 | 207 | 246 | 265 | 245 | |||
| Cash from Investing Activity + | -42 | -114 | -195 | -112 | -158 | -155 | -160 | |||
| Cash from Financing Activity + | -37 | -43 | 31 | -100 | -85 | -99 | -99 | |||
| Net Cash Flow | 0 | -1 | 3 | -4 | 3 | 12 | -14 | |||
| Free Cash Flow | 79 | -1 | -37 | 52 | 101 | 180 | 134 | |||
| CFO/OP | 101% | 100% | 74% | 98% | 92% | 85% | 70% |
Financials of Concord Biotech Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 165 | 182 | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 |
| Inventory Days | 276 | 321 | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 |
| Days Payable | 108 | 129 | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 |
| Cash Conversion Cycle | 334 | 374 | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 |
| Working Capital Days | 195 | 209 | 275 | 177 | 159 | 177 | 163 | 153 | 166 | 193 |
| ROCE % | 37% | 25% | 25% | 32% | 21% | 26% | 28% | 28% |